U.S. Industrials Stock News

If you are wondering whether Payoneer Global's current share price reflects its true worth, this article walks through what the numbers are actually saying about value. The stock last closed at US$4.32, after returns of a 20.1% decline over the past week, a 31.4% decline over the past month, a 20.6% decline year to date and a 49.5% decline over the past year. Recent share price moves come against a backdrop of ongoing interest in digital cross border payments and financial infrastructure for...

Recent analyst upgrades and steady upward revisions to earnings estimates have put Five Below (FIVE) in focus, as investors weigh how stronger sentiment and ongoing store openings might influence the stock’s risk and return profile. See our latest analysis for Five Below. The share price has been moving sharply, with a 20.55% 1 month share price return and a 35.56% 3 month share price return. The 1 year total shareholder return of about 157% points to strong momentum around store openings and...

In February 2026, Garmin reported fourth-quarter 2025 sales of US$2,124.96 million and net income of US$528.68 million, alongside full-year 2025 sales of US$7.25 billion and net income of US$1.66 billion, while proposing a higher US$4.20 per-share dividend and completing a US$244.60 million buyback under its prior repurchase plan. Management also issued 2026 guidance calling for US$7.90 billion in revenue and operating income above US$2.00 billion, launched new high-end motorsports and...

PACS Group (PACS) just wrapped up FY 2025 with Q4 revenue of US$1.4b and basic EPS of US$0.38, supported by trailing twelve month revenue of US$5.3b and EPS of US$1.23 that has been tied to very large year on year earnings growth of 243.5%. Over recent periods, the company has seen quarterly revenue move from US$1.21b in Q4 2024 to US$1.36b in Q4 2025, while quarterly EPS went from US$0.24 to US$0.38. This sets up a results season where strong reported earnings growth, margin improvement to...

GeneDx Holdings (NasdaqGS:WGS) Chief Operating Officer Bryan Dechairo has sold his entire direct shareholding in an open market transaction. The sale was executed under a Rule 10b5-1 trading plan and leaves Dechairo with no direct equity interest in the company. This insider transaction comes as GeneDx continues to report business growth and operational progress. The move comes at a time when GeneDx shares last closed at $79.71, with the stock showing mixed performance across time frames...

Warner Bros. Discovery (WBD) has capped FY 2025 with fourth quarter revenue of US$9.5b and a basic EPS loss of US$0.10, setting the tone for a year where profitability on a trailing basis has been supported by a sizeable one off gain. The company has seen quarterly revenue range between US$9.0b and US$9.8b across 2025, with EPS swinging from a loss of US$0.18 in Q1 to a profit of US$0.64 in Q2 before reverting to losses in Q3 and Q4. This leaves investors focusing on how much of the reported...

BrightSpring Health Services (BTSG) just closed FY 2025 with fourth quarter revenue of US$3.6b and basic EPS of US$0.24, while net income from continuing operations, excluding extra items, came in at US$49.3m. The company has seen quarterly revenue move from US$3.1b and EPS of US$0.08 in Q4 2024 to US$3.6b and EPS of US$0.24 in Q4 2025, with trailing twelve month EPS at US$0.53 and net income of US$106.3m on US$12.9b in revenue. This puts the latest report firmly in focus for anyone tracking...

ESAB (NYSE:ESAB) has introduced the Ruffian EMP 270G engine-driven welding generator at CONEXPO-CON/AGG 2026. The unit features advanced inverter technology and more than 100 customer-requested features. The product was developed in collaboration with Linde, with exclusive offerings tied to the trade show launch. ESAB, listed on the NYSE under the ticker ESAB, is a welding and cutting equipment company with a focus on industrial and construction applications. By rolling out the Ruffian EMP...

Iovance Biotherapeutics recently reported Q4 2025 and full-year 2025 results, with revenue rising to US$86.77 million for the quarter and US$263.50 million for the year, alongside lower quarterly net loss and loss per share compared with 2024. At the same time, the company highlighted positive early lifileucel data in aggressive soft tissue sarcomas and secured FDA Fast Track designation for non-small cell lung cancer, underscoring how its first commercial TIL therapy Amtagvi is increasingly...

Earlier this month, Ecolab’s board reshaped its senior team by adding the President title to Chairman and CEO Christophe Beck and splitting the chief operating officer role between Darrell R. Brown as Co-COO – Global Markets and Gregory B. Cook as Co-COO – Global Businesses, while director Victoria J. Reich decided not to stand for re-election and the company affirmed its US$0.73 quarterly dividend. These leadership changes, alongside a new shelf registration for debt securities, suggest...

Applied Optoelectronics (AAOI) closed out FY 2025 with fourth quarter revenue of US$134.3 million and a basic EPS loss of US$0.03, alongside net income excluding extra items of a US$2.0 million loss. This puts the focus squarely on how efficiently that top line is being converted into earnings. The company has seen quarterly revenue move from US$65.2 million in Q3 2024 to US$100.3 million in Q4 2024, then to US$99.9 million in Q1 2025, US$103.0 million in Q2 2025, US$118.6 million in Q3 2025...

Perella Weinberg Partners recently reported quarterly revenues of US$219.2 million, a 2.9% year-on-year decline that still exceeded analyst estimates by a very large margin, alongside an earnings beat. The results highlight how the firm’s operational execution outpaced expectations even as headline revenue slipped, offering a more nuanced picture of performance for investors. Next, we’ll examine how this better-than-expected revenue performance shapes Perella Weinberg Partners’ investment...

In the fourth quarter and full year ended December 31, 2025, Jones Lang LaSalle reported higher sales and net income year over year, while also completing a multi‑year share repurchase program totaling 6.80 million shares for US$1.40 billion since its November 2019 authorization. The combination of earnings exceeding analyst expectations and management’s plan to direct more capital toward buybacks in 2026 highlights a greater emphasis on capital return alongside operational growth in...

Community Trust Bancorp recently highlighted a quarterly dividend of US$0.53 per share, implying a 3.43% yield and reflecting five consecutive years of annual dividend increases averaging 5.32%. Alongside this dividend profile, the company is guided by a Zacks Consensus Estimate pointing to fiscal 2026 earnings of US$5.79 per share, suggesting investors are closely watching how income and earnings trends align. With this backdrop of consistent dividend growth, we’ll examine how the company’s...

In February 2026, STAAR Surgical announced that the FDA approved an expanded age indication for its EVO/EVO+ Visian Implantable Collamer Lenses, extending U.S. use from ages 21–45 to 21–60 following three-year safety data. This broader label meaningfully enlarges the potential U.S. candidate pool for EVO ICL, especially among adults aged 46–60 who were previously excluded. We’ll now examine how opening EVO ICL access to patients up to age 60 could reshape STAAR Surgical’s longer-term...

Lantheus Holdings (LNTH) just posted fourth quarter results that topped Wall Street expectations on both revenue and earnings, while issuing 2026 guidance that sits below consensus and reflects expected pressure on key products. See our latest analysis for Lantheus Holdings. The latest earnings beat and guidance update come after a sharp rebound in the 3‑month share price return of 27.25% and a 1‑month share price return of 12.97%, even though the 1‑year total shareholder return is still down...

If you are wondering whether Hinge Health at around US$42.76 is offering good value or asking too much, you are not alone. This article is designed to help you frame that question clearly. Over the short term, the stock has moved, with a 3.5% return over the last 7 days, 13.6% over the last 30 days, and a 6.1% decline year to date. These changes can influence how investors think about both upside and risk. Recent coverage has focused on Hinge Health as a listed digital healthcare name and on...

Healthpeak Properties (DOC) is in focus after confirming that CEO Scott Brinker will speak at the Citi 2026 Global Property CEO Conference, while the company continues work on the Janus Living senior housing REIT IPO. See our latest analysis for Healthpeak Properties. Recent interest around the CEO’s Citi conference appearance and the Janus Living IPO work comes as the stock shows a 1-day share price return of 0.97% and a 7-day share price return of 4.06%. The 1-year total shareholder return...

Coupang FY 2025 Results Set Up a Mixed but Margin Focused Story Coupang (CPNG) closed FY 2025 with fourth quarter revenue of US$8.8b and a basic EPS loss of US$0.01, as net income excluding extra items came in at a US$26m loss against a backdrop of growing full year scale. The company has seen quarterly revenue step up from US$7.9b in Q4 2024 to between US$7.9b and US$9.3b through 2025. Basic EPS has moved between a profit of US$0.06 and a small loss in the latest quarter, setting up a TTM...

If you are wondering whether Nova's share price still reflects good value after a strong run, this article is for you. We will walk through what the current market price might be implying about the business. Nova's stock last closed at US$438.86, with a 7 day return of a 0.5% decline, a 30 day return of a 9.9% decline, a year to date return of 26.3% and a 1 year return of 83.5%, while the 3 year return is very large and the 5 year return is also very large. Recent news coverage around Nova...

Opera (NasdaqGS:OPRA) posts FY 2025 results Opera (NasdaqGS:OPRA) closed out FY 2025 with fourth quarter revenue of US$176.7 million and basic EPS of US$0.62, rounding off a trailing twelve month run of US$614.4 million in revenue and EPS of US$1.21 as earnings grew 34.1% over the past year. The company has seen revenue move from US$480.6 million on a trailing basis at the end of 2024 to US$614.4 million by the end of 2025, while trailing net profit margin edged up from 16.8% to 17.6%. With...

ABM Industries, NYSE:ABM, is repositioning itself as a defensive, cash-focused services company. Management is prioritizing margin protection through wage inflation management and contract repricing. The company is reshaping its portfolio with selective divestitures and greater emphasis on technology-enabled services. ABM Industries, trading at $44.5, is presenting itself as a steadier, lower volatility option within the outsourced facilities and services space. The effort is playing out...

Innodata (INOD) has just wrapped up FY 2025 with fourth quarter revenue of US$72.4 million and basic EPS of US$0.28, alongside trailing twelve month revenue of US$251.7 million and EPS of US$1.01. The company has seen quarterly revenue move from US$52.2 million in Q3 2024 to US$72.4 million in Q4 2025. Basic EPS has ranged from US$0.60 in Q3 2024 to between US$0.23 and US$0.28 across the 2025 quarters, setting up a picture where growing sales are rubbing against tighter margins and leaving...

If you are wondering whether SoFi Technologies shares are offering good value right now, you are not alone. This article will walk through what the current price actually reflects. The stock recently closed at US$17.76, with returns of a 6.6% decline over 7 days, a 27.8% decline over 30 days, a 35.3% decline year to date, but a 22.7% gain over 1 year and a very large gain over 3 years. These moves have come as SoFi remains a widely watched name in US fintech, with ongoing attention on its...